Precision medicine enables us to offer more powerful treatments for a variety of cancers, with new advances taking place all the time.

Here's a sampling of some of our most promising breakthroughs:

Lung Cancer – We have expanded our knowledge of the biology of lung cancer and the genes that promote it. We have demonstrated that lung cancer can respond to immunotherapy drugs like Keytruda. We now understand that each tumor is unique, and we are approaching the capability of pinpointing targeted therapy for each tumor and each patient, leading to the day when lung cancer is just a chronic disease.

Breast Cancer - Breast cancer is made up of many types and subtypes. The move to precision medicine and molecular profiling tools enables doctors to match each patient with the most effective treatment. We’re seeing a new focus on immunotherapy with checkpoint inhibitors, as well as drugs that target abnormalities in the cancer cell that are unique to each patient. This will mean less chemotherapy, less surgery, less radiation, fewer side effects and less resistance.

Leukemia, Lymphoma and Myeloma – Groundbreaking research with CAR T cell therapy is changing the way we treat blood cancers. CAR T cells are specially-engineered immune cells designed to recognize specific proteins in cancer cells. This new approach has the potential of unleashing each patient's immune system to destroy cancer and prevent it from returning.

CAR T cell therapy is also showing tremendous potential in solid tumors, including brain cancer. City of Hope is the only facility employing CAR T cell trials by injecting the immune cells directly into the tumors. Early results have been nothing short of remarkable.

Similar progress is taking place in the treatment of bladder cancer, colorectal cancer, liver cancer and prostate cancer.  Precision medicine is offering new hope to patients with advanced cancer, as well as for those whose cancer has recurred and for patients for whom conventional treatments have failed.

In a growing number of cases, patients at City of Hope undergo molecular testing. This is now a routine procedure for patients with breast, lung and colorectal cancers, as well as those being treated for melanoma or leukemia. Such testing will become increasingly common as our knowledge of genomics expands and is shared among clinicians and researchers.